Phathom Pharmaceuticals Net Income Over Time
| PHAT Stock | USD 12.82 0.04 0.31% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Phathom Pharmaceuticals Performance and Phathom Pharmaceuticals Correlation. Is there potential for Pharmaceuticals market expansion? Will Phathom introduce new products? Factors like these will boost the valuation of Phathom Pharmaceuticals. Anticipated expansion of Phathom directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about Phathom Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.76) | Revenue Per Share | Quarterly Revenue Growth 2.027 | Return On Assets | Return On Equity |
The market value of Phathom Pharmaceuticals is measured differently than its book value, which is the value of Phathom that is recorded on the company's balance sheet. Investors also form their own opinion of Phathom Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Phathom Pharmaceuticals' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Phathom Pharmaceuticals' market value can be influenced by many factors that don't directly affect Phathom Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Phathom Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Phathom Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Phathom Pharmaceuticals' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Net Income Analysis
Compare Phathom Pharmaceuticals and related stocks such as Nurix Therapeutics, Kodiak Sciences, and Xencor Inc Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NRIX | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (21.7 M) | (43.2 M) | (117.2 M) | (166 M) | (143.9 M) | (193.6 M) | (264.5 M) | (238 M) | (226.1 M) |
| KOD | (17.1 M) | (17.1 M) | (17.1 M) | (17.1 M) | (17.1 M) | (17.1 M) | (17.1 M) | (27.9 M) | (41.4 M) | (47.4 M) | (133.1 M) | (267 M) | (333.8 M) | (260.5 M) | (176.2 M) | (158.6 M) | (166.5 M) |
| XNCR | (11.2 M) | (11.2 M) | (8.6 M) | (60.3 M) | (16.4 M) | (17.6 M) | 23.6 M | (48.9 M) | (70.4 M) | 26.9 M | (63.5 M) | 82.6 M | (55.2 M) | (126.1 M) | (232.6 M) | (209.4 M) | (198.9 M) |
| URGN | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (4.6 M) | (12.7 M) | (1.9 M) | (20 M) | (75.7 M) | (105.1 M) | (128.5 M) | (110.8 M) | (109.8 M) | (102.2 M) | (126.9 M) | (114.2 M) | (108.5 M) |
| BCAX | (37.8 M) | (37.8 M) | (37.8 M) | (37.8 M) | (37.8 M) | (37.8 M) | (37.8 M) | (37.8 M) | (37.8 M) | (37.8 M) | (37.8 M) | (37.8 M) | (37.8 M) | (52 M) | (68 M) | (61.2 M) | (64.3 M) |
| OCS | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (18.6 M) | (38.7 M) | (88.8 M) | (85.8 M) | (77.2 M) | (81.1 M) |
| BBOT | (43.4 K) | (43.4 K) | (43.4 K) | (43.4 K) | (43.4 K) | (43.4 K) | (43.4 K) | (43.4 K) | (43.4 K) | (43.4 K) | (43.4 K) | (43.4 K) | (3.5 K) | (64.7 M) | (74.3 M) | (66.8 M) | (63.5 M) |
| SEPN | (27.7 M) | (27.7 M) | (27.7 M) | (27.7 M) | (27.7 M) | (27.7 M) | (27.7 M) | (27.7 M) | (27.7 M) | (27.7 M) | (27.7 M) | (27.7 M) | (27.7 M) | 4.2 M | (71.8 M) | (64.6 M) | (61.4 M) |
| SANA | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (130.8 M) | (278.6 M) | (344.2 M) | (266.4 M) | (283.3 M) | (266.8 M) | (240.1 M) | (252.1 M) |
| ANAB | (5.5 M) | (5.5 M) | (5.5 M) | (5.5 M) | 232 K | (5.4 M) | (4.3 M) | (30.1 M) | (61.7 M) | (97.3 M) | (19.9 M) | (57.8 M) | (128.7 M) | (163.6 M) | (145.2 M) | (130.7 M) | (124.2 M) |
Phathom Pharmaceuticals and related stocks such as Nurix Therapeutics, Kodiak Sciences, and Xencor Inc Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Phathom Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Phathom Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Phathom Pharmaceuticals | PHAT |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 100 Campus Drive, |
| Exchange | NASDAQ Exchange |
USD 12.82
Additional Tools for Phathom Stock Analysis
When running Phathom Pharmaceuticals' price analysis, check to measure Phathom Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Phathom Pharmaceuticals is operating at the current time. Most of Phathom Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Phathom Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Phathom Pharmaceuticals' price. Additionally, you may evaluate how the addition of Phathom Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.